Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/8114
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLord, J.-
dc.contributor.authorFlight, I.-
dc.contributor.authorNorman, R.-
dc.date.issued2003-
dc.identifier.citationCochrane Database of Systematic Reviews, 2003; 2003(2):www 1-www 79-
dc.identifier.issn1469-493X-
dc.identifier.issn1464-780X-
dc.identifier.urihttp://hdl.handle.net/2440/8114-
dc.descriptionCopyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.-
dc.description.abstractPolycystic ovary syndrome (PCOS) is characterised by anovulation, hyperandrogenaemia and insulin resistance. Hyperinsulinaemia is known to be associated with an increase in cardiovascular risk and the development of diabetes mellitus. If insulin sensitising agents such as metformin are effective in treating features of PCOS, then they could have wider health benefits than just treating the symptoms of the syndrome.-
dc.description.statementofresponsibilityJ.M. Lord, I.H.K. Flight and R.J. Norman-
dc.language.isoen-
dc.publisherUpdate Software Ltd-
dc.subjectHumans-
dc.subjectPolycystic Ovary Syndrome-
dc.subjectAnovulation-
dc.subjectInositol-
dc.subjectMetformin-
dc.subjectThiazoles-
dc.subjectThiazolidinediones-
dc.subjectChromans-
dc.subjectHypoglycemic Agents-
dc.subjectOvulation Induction-
dc.subjectFemale-
dc.subjectRandomized Controlled Trials as Topic-
dc.subjectRosiglitazone-
dc.subjectPioglitazone-
dc.subjectTroglitazone-
dc.titleInsulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, d-chiro-inositol) for polycystic ovary syndrome-
dc.typeJournal article-
dc.identifier.doi10.1002/14651858.CD003053-
pubs.publication-statusPublished-
dc.identifier.orcidNorman, R. [0000-0002-3118-3896]-
Appears in Collections:Aurora harvest 4
Obstetrics and Gynaecology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.